Last reviewed · How we verify
OBV/PTV/r and DSV
OBV/PTV/r and DSV is a fixed-dose combination of hepatitis C virus (HCV) NS5A inhibitor, NS3/4A protease inhibitor, and NS5B nucleotide polymerase inhibitor that blocks viral replication.
OBV/PTV/r and DSV is a fixed-dose combination of hepatitis C virus (HCV) NS5A inhibitor, NS3/4A protease inhibitor, and NS5B nucleotide polymerase inhibitor that blocks viral replication. Used for Chronic hepatitis C virus (HCV) infection, genotype 1.
At a glance
| Generic name | OBV/PTV/r and DSV |
|---|---|
| Also known as | Viekirax and Exviera |
| Sponsor | Hannover Medical School |
| Drug class | Direct-acting antiviral (DAA) combination |
| Target | HCV NS5A, NS3/4A protease, NS5B polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
This combination targets three essential HCV non-structural proteins to prevent viral RNA replication and protein processing. OBV (ombitasvir) inhibits NS5A, PTV (paritaprevir) with ritonavir (r) boosts protease inhibition of NS3/4A, and DSV (dasabuvir) inhibits NS5B polymerase. The triple mechanism provides high barrier to resistance and achieves sustained virologic response in HCV genotype 1 patients.
Approved indications
- Chronic hepatitis C virus (HCV) genotype 1 infection
Common side effects
- Fatigue
- Headache
- Nausea
- Pruritus
- Elevated bilirubin
Key clinical trials
- MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV (PHASE4)
- Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B (PHASE4)
- PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis (PHASE4)
- A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OBV/PTV/r and DSV CI brief — competitive landscape report
- OBV/PTV/r and DSV updates RSS · CI watch RSS
- Hannover Medical School portfolio CI